COLORECTAL MALIGNANCIES Divina B. Esteban, M.D., FPSMO Rizal Medical Center.

Slides:



Advertisements
Similar presentations
Surveillance/ Screening Colonoscopy for Colorectal Cancer
Advertisements

Polyps – Where do they come from and what do you do with them?!
AJCC Staging Moments AJCC TNM Staging 7th Edition Rectal Case #3 Contributors: J. Milburn Jessup, MD Cancer Diagnosis Program, DCTD, NCI, Rockville, Maryland.
Prof. Faisal Ghani Siddiqui FCPS; PGDip-bioethics; MCPS-HPE
Eugen Divjak Mentor: A. Žmegač Horvat
Role of colonoscopy in the treatment of malignant polyps Pathology of malignant colorectal polyps Assessing the risk of residual disease post-polypectomy.
The Adenoma/Carcinoma Sequence in the Colon
Update on Screening of Gastrointestinal Diseases Niraj Jani, M.D. Greater Baltimore Medical Center 1/30/15.
Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007.
COLORECTAL CARCINOMA Bernard M. Jaffe, MD Professor of Surgery Emeritus.
Colorectal Cancer Ramon Garza III, M.D.. Colorectal CA DNA Sequencing Mismatch Repair Genes Genomics Role of PCR and FISH in Colon CA.
Colon Cancer Basic Science 9/21/05. Colon and rectal neoplasms are characterized by: Consist of the third most common site of new cancer cases and deaths.
CHARACTERISTICS OF PATIENTS WITH COLORECTAL CANCER IN NORTHWESTERN GREECE Dimitrios Christodoulou, Ioannis Mitselos, Chrisanthi Tzika, Epameinondas V.
COLORECTAL CANCER Epidemiology: CRC is the 3rd cancer killer after:

Screening and Early Diagnosis of Colorectal Cancer
Colorectal Cancer (CRC)
Colorectal cancer in Norway Maria Mai Ingvild Hvalby.
Tumors of the bile ducts
Colon Cancer by Bryan E. Mosora, D.O..
Colorectal cancer Khayal AlKhayal MD,FRCSC
Colorectal Cancer.
General Medicine Subspecialty Conference Colon Cancer Screening General Medicine Subspecialty Conference Colon Cancer Screening Selim Krim, MD Assistant.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria COLORECTAL CANCER.
D. M. Kruss MD Kill the Cancer Do Screening now! Daniel M. Kruss, M.D. Kill the Cancer Do Screening now! Daniel M. Kruss, M.D.
Cancer of the Digestive System Colorectal Cancer.
Colon Cancer Daniel A. Nikcevich, MD, PhD Duluth Clinic Cancer Center January 26, 2009.
High risk population in GI field how we can find them? Ahmad Shavakhi MD Associate professor of gastroenterology.
Colorectal carcinoma Dr.Mohammadzadeh.
Colorectal cancer Khayal AlKhayal MD,FRCSC Assistant professor of Surgery Consultant Colorectal surgeon 9/11/2015Shwartz.
Interventions for Clients with Colorectal Cancer
Slides last updated: June 2015 CRC: CLINICAL FEATURES.
Slides last updated: March 2015 CRC: STAGING. How colorectal cancer (CRC) is staged 1 Stage describes the extent of cancer, and is one of the most important.
Common small and large intestinal surgical diseases Part II
Colon Cancer. Epidemiology 3 rd most common cancer in males and females. Accounts for 11% of cancer deaths. In 2000, 130,200 cases (colon and rectum).
1 Colorectal Cancer # 2 Cancer Killer # 2 Cancer Killer SCREENING SAVES LIVES.
COLON CANCER A MAJOR ISSUE IN ALASKA. A common malignancy 200,000 cases in the U. S. in ,000 cases in the U. S. in 2008 Greater than 50 new cases.
Colorectal Cancer. Colorectal cancer - statistics Leading causes of cancer death in the US Male Female Lung – 31% Lung – 25% Prostate – 11% Breast – 11%
1 Colorectal Cancer # 2 Cancer Killer # 2 Cancer Killer SCREENING SAVES LIVES.
COLORECTAL CANCER Ozlem Uysal-Sonmez, MD Yeditepe University Hospital Department of Medical Oncology.
Cancer colon.
Change in bowel habits … 60 year old male Complains of progressive constipation for the past 6 months.
Better Health. No Hassles. Colorectal Cancer Facts – The 2 nd leading cause cancer-related deaths in the Nation – Highly preventable – Caused 49,920 deaths.
GI Tutorial. General Structure Mucosa –Epithelium –Lamina Propria –Muscularis Mucosa Submucosa –Connective tissue, blood vessels, nerve plexus Muscularis.
Pathology Report Colorectal Cancer Sahar Najibi April 11 th, 2008.
A 58 years old man presents with melena. What would you ask him?
Colon Cancer. Multihit Concept Clinical Information Clinical Information 1. Patient identification a. Name b. Identification number c. Age (birth date)
Colorectal Cancer Proposal of a Screening Program for Developing Countries with Emphasis on Costs.
Colon Cancer Matt Anderson, MD MSc Friday Teaching Seminar September 24, 2004.
16/12/2012 Mr. Ravi-Kumar Stafford General Hospital1 ABC of CRC (Colo-Rectal Carcinoma) Mr Ravi-Kumar Consultant Surgeon Coloproctology, Laparoscopy &
TNM Staging: Colon and Rectum
Definition Signs & symptoms Treatment Root of the disease.
Care of Patients with Noninflammatory Intestinal D/O
Interventions for Clients with Colorectal Cancer.
Laparoscopic vs. Conventional Resections for Colorectal Carcinoma 2LT Pil (Pete) Kang New York University School of Medicine 28 September 2000.
Colon Cancer. What is Colon Cancer?  Cancer that begins in the colon or rectum  The colon and rectum are both parts of the large intestine  The third.
The Malignant Polyp Handout Version Hans Elzinga, MD Program Director- Advanced Procedures in Family Medicine Fellowship Salud Family Health Center-Longmont,
Case. Kreem is 53 year old man who is quite healthy with no previous illness. He has noticed changes in his bowel habits for the last few months, with.
POLYPS CHOLORECTAL CANCER M. DuBois Fennal, PhD, RN, CNS.
Colon Cancer The Bottom Line
Colorectal Cancer: Risk Prevention and Diagnosis
Professor Dr. Sabeha Al-Bayati MBCHB,CABM,FRCP
Cancer colon.
Module 4: Colorectal Cancer
Colorectal Cancer.
Polyps of the Colon and Rectum
Colonic polyps and tumors
Changes in TNM 8 To be used from
Presentation transcript:

COLORECTAL MALIGNANCIES Divina B. Esteban, M.D., FPSMO Rizal Medical Center

Epidemiology : Worldwide incidence varies from: 3.4/100,000 - Nigeria to 35.8/100,000 - Connecticut, USA

Philippine data: * Colon Cancer : –5th most common (males) /100,000 –7th among females (9.5/100,000) –6th for both sexes ( 10.4/100,000 ) –ASR in Filipino migrants to USA > ASR in the Philippines –Intermediate incidence between Thailand & high rates in Asia, USA & Europe * Cancer In The Phil. Volume III. 2002

Philippine data * Rectal cancer –9th most common (M) - 7.9/100,000 –11th most common (F) - 5.7/100,000 –11th for both sexes - 6.7/100,000 – ASR in Filipino migrants > than those observed in the Philippines –Int. inc. bet. low rates in Thailand and high rates in Asia, Europe & USA * Cancer In The Philippines Vol.. III. 2002

Leading Cancer Sites, Females, DOH - Rizal & PCS - Manila Cancer Registries Leukemias Stomach Rectum Liver Thyroid Colon Ovary Lung Cervix Breast ASR/100,

2005 Estimates* 8585 new colorectal cancer cases Males: 4737 Females: deaths from colorectal cancer Males: 3064Females: 2494 * 2005 Philippine Cancer Facts & Estimates. PCSI Females: 3

Philippine Survival Data* Colon Cancer Overall median survival: 49 months 5-year survival rate: 47.72% 10-year survival rate: 32.38% Rectal Cancer Overall median survival: 24 months 5-year survival rate: 19.45% 10-year survival rate: 5.84% * Mapua et al, Population-based Cancer Survival, PCS-MCR.

RISK FACTORS Familial adenomatous polyposis (FAP) Adenomatous polyps in colon/ rectum Chronic ulcerative colitis Familial cancer syndrome Family history High -meat and high fat/ low fiber diet

SCREENING Guidelines Screening for >50 years old: –Annual FOBT –Flexible sigmoidoscopy or DCBE every 5 yrs Screening for 1st degree relative w/ cancer –Flexible sigmoidoscopy, DCBE or colonoscopy every 5-10 years from age 50 years –If relative was Dx before age 55, colonoscopy should be done at age 50 or 10 years prior to index case Screening for (+) hx of adenoma or CA Screening for (+) ulcerative colitis Screening for HNPCC and FAP

SCREENING Guidelines cont. Screening for pts with (+) hx of adenoma or CA : –Colonoscopy, DCBE or flexible sigmoidoscopy every 3-5 years –Repeat colonoscopy within 1 yr if fragmented polyp > 1 cm, high gr dysplasia, villous changes; multiple > 2; (+) FH; more than 60 yrs old –Flexible sigmoidoscopy or DCBE every 5 yrs

SCREENING Guidelines cont. Screening for pts. with ulcerative colitis If more than 8 yrs duration: FOBT every 2 yrs –Flexible sigmoidoscopy every 5 yrs from age 50 years Screening for HNPCC and FAP –Genetic consult –Annual colonoscopy from age 25 years

SCREENING Guidelines for high risk groups & symptomatic patients: –Colon Cancer: Fecal blood tests Colonoscoopy +/- biopsy Barium enema –Rectal Cancer Digital rectal examination Proctosigmoidoscopy

Clinical Presentation Colon Cancer - Right-sided Lesion : ( bulky, exophytic, large diameter, more fluid content) Abdominal pain Diarrhea Occult gastrointestinal bleeding - anemia Weight loss Signs of low small bowel obstruction Mass in the right iliac fossa

Clinical Presentation Colon Cancer - Left-sided Lesion: ( annular or infiltrating, small diameter, semi-solid to solid contents) Obstruction Bleeding or bloody stools Perforated pericolic abscesses or peritonitis Change in bowel habits Abdominal discomfort

Clinical Presentation Rectal Cancer: Rectal bleeding (bright red) Change in bowel habits constipation / diarrhea Feeling of incomplete emptying after BM ; unproductive urge to defecate; tenesmus Persistent narrowing of stools Rectal mass Unexplained weight loss

Diagnosis Careful history ( unexplained weight loss, anemia, change in bowel habits, abdominal pain, constipation, etc) Physical examination including digital rectal examination (DRE) Colonoscopy, proctosigmoidoscopy +/- bx Barium enema Tumor markers : CEA

PATHOLOGY Histological Classification 1. Epithelial Tumors Adenocarcinoma Mucinous Adenocarcinoma Signet-ring cell carcinoma Squamous cell carcinoma Adenosquamous carcinoma Small cell carcinoma Undifferentiated carcinoma

Histological Classification (cont) 2. Carcinoid Tumors 3. Non-epithelial tumors (Leiomyosarcoma) 4. Hematopoietic & Lymphoid Neoplasms 5. Unclassified Tumors

TNM STAGING Primary Tumor (T) T0 No evidence of primary tumor Tis CIS :inv of lamina propria or muscularis mucosa T1 Tumor invades the submucosa T2 Tumor invades the muscularis propria T3 Tumor invades thru m. propria into subserosa/to nonperitonealized pericolic or perirectal tissues T4 Tumor directly inv. other organs/perforates the visceral peritoneum

TNM STAGING (cont.) Regional Lymph nodes (N) Nx Regional LN cannot be assessed N0 No regional LN metastasis N1 Metastasis to 1-3 regional LN N2 Metastasis in 4 or more pericolic LN N3 Metastasis in any LN along the course of a named vascular trunk &/or mets. to apical node(s)

TNM STAGING (cont.) Distant Metastasis (M) Mx distant metastasis cannot be assessed M0 No distant metastasis M1 Distant metastasis

TNM STAGING (cont.) Stage Groupings: TNM Astler-Coller modified 0 Tis N0 M0n/a I T1 N0 M0 Stage A T2 N0 M0 Stage B1 II T3 N0 M0 Stage B2 T4 N0 M0 Stage B3 III Any T N1 M0 Stage C1- C3 Any T N2 M0 IVAny T Any N M1 Stage D

PROGNOSTIC FACTORS: 1Disease extension beyond the rectal wall –for (+)LN but tumor confined to wall (Tis-2 N1-3), loc. recurrence = 20-40% –for (-) LN but w/ extension beyond wall (T3 or T4A N0 or T4B N0), loc. recur. = 20-35% – for (+) LN & (+) ext. beyond wall (T4N1-3, T4b N1-3), loc. recur. = % – Nodal involvement PROGNOSTIC FACTORS

PROGNOSTIC FACTORS cont. 2 Lymph node involvement 3 Extrarectal extension = Amount of uninvolved tissue (circumferential or radial margins) Define the extraluminal extent of tumors Measure the narrowest radial margin

Prognostic Factors cont. Histologic grade Stage of tumor Depth of invasion Frequency of nodal involvement Number of lymph nodes involved Bowel obstruction 2 o to tumor Tumor perforation

PATTERNS OF FAILURE after a curative resection Local recurrence –30-50% in MAC B3, C2 and C3 lesions –15-20% in many B2 and most C1 lesions Peritoneal seedings - Least common in rectal primaries Systemic metastasis –Rectal Cancer: Liver and Lung due to venous drainage –Colon CA: Initial mets in the liver (venous drainage via the portal system)

TREATMENT SCHEMA Colon Cancer Suspect Rectal Cancer Suspect